Targets › S1PR3
1 program from 1 company in 4 trials: 2 Phase 4, 1 Phase 3, 1 Phase 2; Neurology, Metabolic and endocrine, Oncology; next expected readout Sep 2027.
Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. (UniProt, Q99500)
Open in Phaseline: the race on S1PR3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Fingolimod Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent | S1PR5, S1PR2, S1PR4, S1PR3, S1PR1 | Phase 4 | Multiple Sclerosis; Diabetes Mellitus, Type 2; Non Small Cell Lung Cancer | Sep 2027 |
Multiple Sclerosis (2) Diabetes Mellitus, Type 2 (1) Non Small Cell Lung Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.